Aridis Pharmaceuticals Inc. (ARDS): Price and Financial Metrics
Aridis Pharmaceuticals Inc. (ARDS)
Today's Latest Price: $7.02 USD
Updated Jun 3 6:55pm
Add ARDS to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 214 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
ARDS Stock Summary
- The ratio of debt to operating expenses for Aridis Pharmaceuticals Inc is higher than it is for about only 0.37% of US stocks.
- With a price/sales ratio of 74.63, Aridis Pharmaceuticals Inc has a higher such ratio than 97.46% of stocks in our set.
- As for revenue growth, note that ARDS's revenue has grown -62.93% over the past 12 months; that beats the revenue growth of just 2.24% of US companies in our set.
- Stocks that are quantitatively similar to ARDS, based on their financial statements, market capitalization, and price volatility, are ALPN, GRTS, PTI, UMRX, and SYBX.
- ARDS's SEC filings can be seen here. And to visit Aridis Pharmaceuticals Inc's official web site, go to www.aridispharma.com.
ARDS Stock Price Chart More Charts
ARDS Price/Volume Stats
| Current price | $7.02 | 52-week high | $12.40 |
| Prev. close | $7.30 | 52-week low | $3.80 |
| Day low | $7.02 | Volume | 700 |
| Day high | $7.03 | Avg. volume | 10,571 |
| 50-day MA | $6.78 | Dividend yield | N/A |
| 200-day MA | $6.59 | Market Cap | 62.64M |
Aridis Pharmaceuticals Inc. (ARDS) Company Bio
Aridis Pharmaceuticals Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb that is in Phase IIa trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 to treat infections caused by A. baumannii; AR-201, an anti- respiratory syncytial virus F-protein mAb; and AR-501, an anti-infective therapy to manage chronic lung infections in cystic fibrosis patients and acute pneumonia in HAP and VAP patients. The company was founded in 2003 and is based in San Jose, California.
Loading social stream, please wait...